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Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced
chemotaxis and proliferation of chronic lymphocytic
leukemia cells
J Yu1,3, L Chen1,3, Y Chen1, MK Hasan1, EM Ghia1, L Zhang1, R Wu1, LZ Rassenti1, GF Widhopf1, Z Shen2, SP Briggs2 and TJ Kipps1
Wnt5a can activate Rho GTPases in chronic lymphocytic leukemia (CLL) cells by inducing the recruitment of ARHGEF2 to ROR1. Mass
spectrometry on immune precipitates of Wnt5a-activated ROR1 identified 14-3-3ζ, which was confirmed by co-immunoprecipitation.
The capacity of Wnt5a to induce ROR1 to complex with 14-3-3ζ could be blocked in CLL cells by treatment with cirmtuzumab, a
humanized mAb targeting ROR1. Silencing 14-3-3ζ via small interfering RNA impaired the capacity of Wnt5a to: (1) induce recruitment of
ARHGEF2 to ROR1, (2) enhance in vitro exchange activity of ARHGEF2 and (3) induce activation of RhoA and Rac1 in CLL cells.
Furthermore, CRISPR/Cas9 deletion of 14-3-3ζ in ROR1-negative CLL cell-line MEC1, and in MEC1 cells transfected to express ROR1 (MEC1-
ROR1), demonstrated that 14-3-3ζ was necessary for the growth/engraftment advantage of MEC1-ROR1 over MEC1 cells. We identified a
binding motif (RSPS857SAS) in ROR1 for 14-3-3ζ. Site-directed mutagenesis of ROR1 demonstrated that serine-857 was required for the
recruitment of 14-3-3ζ and ARHGEF2 to ROR1, and activation of RhoA and Rac1. Collectively, this study reveals that 14-3-3ζ plays a critical
role in Wnt5a/ROR1 signaling, leading to enhanced CLL migration and proliferation.
Leukemia (2017) 31, 2608–2614; doi:10.1038/leu.2017.132
INTRODUCTION
ROR1 is a developmentally restricted, type I tyrosine kinase-like
orphan receptor expressed on the neoplastic cells of a variety of
different cancers,1 including chronic lymphocytic leukemia (CLL),
but not on most normal post-partum tissues.2 ROR1 is a receptor
for Wnt5a, which can enhance the survival and growth of CLL
cells.3 Furthermore, MEC1 cells made to express ROR1 (MEC1-
ROR1) had enhanced migration and growth compared with
parental MEC1 cells, which express Wnt5a but lack expression
of ROR1.1 Studies indicate that ROR1 may complex with a known
co-activator of AKT, namely TCL1,3 and accelerate the develop-
ment and progression of leukemia in Eμ-TCL1 transgenic mice.3
Moreover, high-level leukemia cell expression of ROR1 is associ-
ated with accelerated disease progression in patients with CLL.4
On the other hand, silencing ROR1 in CLL cells can decrease
leukemia cell survival.5 These studies imply that ROR1 signaling
can promote leukemia cell activation and survival, and enhance
disease progression in patients with CLL.
Studies indicated that Wnt5a-induced ROR1-dependent activa-
tion of Rho GTPases, RhoA and Rac1, by recruiting guanine-
exchange factors (GEFs), such as ARFGEF2.6 However, ARFGEF2
lacks a SH3 domain, suggesting other proteins are necessary for
ARFGEF2 to complex with ROR1. Defining what protein(s) are
required for recruitment to ROR1 of GEFs, such as ARFGEF2, could
help elucidate the mechanism(s), whereby ROR1 is involved in
enhancing migration and proliferation to promote tumor progres-
sion. Here we provide evidence that ROR1 can recruit ARHGEF2 via
the adapter protein 14-3-3ζ, a member of the 14-3-3 family of
conserved proteins, which plays a critical role in cell signaling
pathways leading to enhanced proliferation, adhesion and survival
of a variety of different cancers.7–9 Moreover, 14-3-3ζ appears
necessary for Wnt5a-induced activation of RhoA and Rac1 via
ARFGEF2, and required for Wnt5a-enhanced ROR1+ leukemia-cell
proliferation, migration, and engraftment.
MATERIALS AND METHODS
CLL specimens and experimental animals
Blood samples were collected from CLL patients at the University of
California–San Diego Moores Cancer Center, who satisfied diagnostic
and immunophenotypic criteria for common B-cell CLL, and who provided
written, informed consent, in compliance with the Declaration of Helsinki
and the Institutional Review Board of the University of California–San
Diego (Institutional Review Board approval number 080918). Peripheral
blood mononuclear cells were isolated as described.6 All experiments
with mice were conducted in accordance with the guidelines of
the National Institutes of Health for the care and use of laboratory
animals, and the University of California–San Diego approved the
study protocol.
Adoptive transfer in immune-deficient mice
We injected 5 × 106 MEC1, MEC1-Δ14-3-3ζ, MEC1-ROR1 or MEC1-ROR1-
Δ14-3-3ζ cells into 6- to 8-week-old Rag2−/−γc
−/− mice (n=6) intraven-
ously. All mice were killed for necropsy 2 weeks later and single-cell
suspensions of splenocytes were purged of red blood cells by hypotonic
lysis in ammonium–chloride–potassium lysis solution, washed, suspended
in 2% (wt/vol) BSA (Sigma-Aldrich, St Louis, MO, USA) in PBS (pH= 7.4) and
stained for surface expression of ROR1 (4A5) and CD19 using optimized
concentrations of fluorochrome-conjugated mAbs. Cells were examined by
four-color, multiparameter flow cytometry using a dual-laser FACSCalibur
(BD Biosciences, San Jose, CA, USA) and the data were analyzed using
FlowJo software (TreeStar, Ashland, OR, USA). The total number of
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leukemia cells per spleen was calculated by determining the percent of
CD19+ROR1+ cells of total lymphocytes by flow cytometry and multiplying
this number by the total spleen cell count.
RESULTS
ROR1 complexes with 14-3-3ζ
We performed mass spectrometry-based proteomic analysis on anti-
ROR1 immune precipitates of lysates prepared from freshly isolated
CLL cells and identified 14-3-3ζ (Supplementary Figure S1A), a
member of the 14-3-3 family of conserved adapter proteins.
Immunoblot analysis of anti-ROR1 or anti-14-3-3ζ immune precipitates
from CLL cell lysates confirmed that ROR1 can complex with 14-3-3ζ
(Figure 1a). Fluorescence confocal microscopy demonstrated that
14-3-3ζ co-localized with ROR1 in freshly isolated CLL cells (Figures 1b
and c). In contrast, control studies did not detect co-localization of
14-3-3ζ with an unrelated surface protein, CD5 (Supplementary Figure
S1B and C). We incubated CLL cells with an anti-ROR1 antibody
(cirmtuzumab) specific for a ROR1 epitope distinct from that recog-
nized by 4A5 and found cirmtuzumab could disrupt the ROR1-14-3-3ζ
complex (Figures 1b and c).
Wnt5a is a ligand for ROR1 that can induce ROR1-dependent
signaling. Culture of CLL cells for 16 h in Wnt5a-deficient media
resulted in the disintegration of the ROR1-14-3-3ζ complex, which
was apparent in CLL cells that were freshly isolated from the
blood. When we treated such cells with Wnt5a, we induced ROR1
to re-associate with 14-3-3ζ. Again, we noted that treatment of the
CLL cells with cirmtuzumab inhibited the capacity of Wnt5a to
induce recruitment of 14-3-3ζ to ROR1 (Figures 1d–f).
14-3-3ζ interacts with ARHGEF2
Prior studies demonstrated that 14-3-3ζ can interact with ARHGEF2,10
facilitating activation of RhoA and Rac1.6 We confirmed that 14-3-3ζ
complexes with ARHGEF2 in freshly isolated CLL cells via immuno-
precipitation and immunoblot analyses (Figure 2a). We hypothesized
that 14-3-3ζ was required for the recruitment and activation of
ARHGEF2 to ROR1, allowing for activation of RhoA and Rac1 following
Wnt5a stimulation. We silenced 14-3-3ζ with specific small interfer-
ing RNA (siRNA) in CLL cells, which were cultured with or without
exogenous Wnt5a. Immunoprecipitation analysis indicated that 14-3-
3ζ-specific siRNA reduced the expression level of 14-3-3ζ and
impaired the capacity of Wnt5a to induce ROR1 to associate with
ARHGEF2 (Figure 2b). Fluorescence confocal microscopy showed that
Wnt5a induced significantly greater co-localization of ROR1 with
ARHGEF2 in CLL cells transfected with control siRNA than in the same
CLL cells transfected with 14-3-3ζ siRNA (si-14-3-3ζ) (Figures 2c and d,
and Supplementary Figures S2A–D). Moreover, treatment of CLL cells
with 14-3-3ζ-specific siRNA, but not control siRNA, inhibited the
capacity of Wnt5a to activate ARHGEF2, as assessed by the capacity
of anti-ARHGEF2 immune precipitates to activate RhoA or Rac1
in vitro (Figure 2e and Supplementary Figures S2E and F). Moreover,
Wnt5a was less effective in activating RhoA and Rac1 in CLL cells
transfected with si-14-3-3ζ than in CLL cells transfected with control
siRNA (Figure 2f and Supplementary Figures S2E and F). These data
imply that 14-3-3ζ was required for the recruitment to ROR1 and
activation of ARHGEF2 in response to Wnt5a.
14-3-3ζ enhances ROR1+ leukemia progression in vitro
MEC1 cells were derived from CLL and have been used as a cell
model for this leukemia.11 However, MEC1 cells lack expression of
Figure 1. ROR1 interacts with 14-3-3ζ. (a) Immunoblot analysis of anti-ROR1 or anti-14-3-3ζ immune precipitates (ip) from lysates of freshly
isolated CLL cells detecting the association of ROR1 with 14-3-3ζ. (b) Co-localization (Yellow, with arrow) of ROR1 (Red) and 14-3-3ζ (Green)
detected by confocal microscopy in freshly isolated CLL cells±Ctrl-IgG or cirmtuzumab, as indicated on the right margin of each row
(Objective: × 100; scale bar= 5 μm). (c) Percentage of co-localization area of ROR1 and 14-3-3ζ in freshly isolated CLL cells±Ctrl-IgG or
cirmtuzumab (n= 3). Data are shown as mean± s.e.m.; **Po0.01, as calculated using two-tailed Student’s t-test. (d) Immunoblot analysis of
anti-ROR1 ip from lysates of cultured CLL cells treated with or without cirmtuzumab, demonstrating the capacity of ROR1 to associate with
14-3-3ζ in response to Wnt5a. (e) Confocal microscopy of serum-starved CLL cells stained for ROR1 and 14-3-3ζ after treatment with or
without Wnt5a and Ctrl-IgG or cirmtuzumab, as indicated on the right margin of each row (Objective: × 100; scale bar= 5 μm). (f) Percentage
of the cell area in which we detect co-localization of ROR1 and 14-3-3ζ by confocal microscopy in serum-starved CLL cells±Wnt5a and
Ctrl-IgG or cirmtuzumab (n= 3). Data are shown as mean± s.e.m.; **Po0.01, as calculated using one-way analysis of variance with Tukey’s
multiple comparisons test.
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ROR1 (Supplementary Figure S3A), but express Wnt5a.6 We made
stable transfectants of MEC1 that expressed full-length ROR1 to
generate MEC1-ROR1 cells and found that MEC1-ROR1 cells had
higher rates of chemokine-induced migration and proliferation
than parental MEC1 cells.1,6
We performed mass spectrometry on anti-ROR1 immune preci-
pitates from MEC1-ROR1 cell lysates and also detected 14-3-3ζ
(Supplementary Figure S3B). To examine the function of 14-3-3ζ,
we extinguished expression of YWHAZ, the gene encoding
14-3-3ζ, in MEC1 or MEC1-ROR1 cells by CRISPR/Cas9 technology
(Supplementary Figures S3C and D). We found that MEC1-ROR1
cells had higher rates of cell proliferation than MEC1 or MEC1-
ROR1-Δ14-3-3ζ cells, which proliferated at rates comparable to
that of MEC1-Δ14-3-3ζ, which lacked the expression of both ROR1
and 14-3-3ζ (Figure 3a). MEC1-ROR1 cells also had higher rates of
cell migration in response to CCL21 than MEC1 or MEC1-ROR1-
Δ14-3-3ζ cells, which again migrated at rates comparable to that
of MEC1-Δ14-3-3ζ lacking expression of both ROR1 and 14-3-3ζ
(Figure 3b). Immunoprecipitation studies revealed that ROR1
interacts with ARHGEF2 in MEC1-ROR1 cells, but not in MEC1-
ROR1-Δ14-3-3ζ cells (Figure 3c). In addition, MEC1-ROR1 cells had
higher levels of activated Rac1 and RhoA than did MEC1 cells or
MEC1-ROR1-Δ14-3-3ζ cells (Figure 3d). These data indicate that
14-3-3ζ is necessary for the recruitment and activation of
ARHGEF2 and the proliferation and migration advantage of
MEC1-ROR1 over MEC1 cells in vitro.
14-3-3ζ enhances ROR1+ leukemia progression in vivo
We examined the capacity of MEC1-ROR1, MEC1, MEC1-Δ14-3-3ζ
or MEC1-ROR1-Δ14-3-3ζ cells to engraft immune-deficient mice.
Two weeks after intravenous infusion of equal numbers of cells,
Rag2− /−γc
− /− mice engrafted with CD19+/ROR1+ MEC1-ROR1 cells
had significantly greater splenomegaly than did littermates
engrafted with MEC1, MEC1-Δ14-3-3ζ or MEC1-ROR1-Δ14-3-3ζ
cells (Supplementary Figure S3E). The proportion of human
CD19+ leukemia cells in each spleen was determined by flow
cytometric analysis of isolated splenocytes (Figure 4a). Multiplying
this number by the total number of splenocytes allowed us to
Figure 2. Interaction of 14-3-3ζ with ARHGEF2. (a) Immunoblot analysis of immune precipitates (ip) generated using lysates of freshly isolated
CLL cells with a mAb specific for 14-3-3ζ, ARHGEF2 as indicated above each lane. The immunoblots were probed with antibodies specific for
14-3-3ζ or ARHGEF2 as indicated on the left margin of each subpanel. (b) Immunoblot analysis of anti-ROR1 ip from lysates of cultured CLL
cells transfected with Ctrl-siRNA (si-Ctrl) or siRNA specific for 14-3-3ζ (si-14-3-3 ζ), detecting the association of ROR1 with ARHGEF2 in the
presence, but not in the absence, of Wnt5a. (c) Co-localization (yellow, with arrow) of ROR1 (red) and ARHGEF2 (green) detected by confocal
microscopy in freshly isolated CLL cells transfected with si-Ctrl or si-14-3-3ζ in the presence of Wnt5a, as indicated. 14-3-3ζ (purple) was
stained to confirm the silencing efficiency (Objective: × 100; scale bar= 5 μm). (d) Percentage of co-localization area of 14-3-3ζ
and ARHGEF2 detected by confocal microscopy in serum-starved CLL cells transfected with Ctrl-siRNA or siRNA specific for YWHAZ,
encoding 14-3-3ζ, in the presence or absence of Wnt5a, as indicated (n= 3). Data are shown as mean± s.e.m.; *Po0.05, as calculated using
one-way analysis of variance with Tukey’s multiple comparisons test. (e) In vitro exchange assay on RhoA or Rac1 of ip from lysates of CLL cells
transfected with Ctrl-siRNA (blue line) or siRNA specific for 14-3-3ζ (purple line) in the presence of Wnt5a, using mAbs specific for ARHGEF2, as
indicated in the bottom of each graph. The green line depicts GTPase activation using buffer alone. (f) Activation of RhoA or Rac1 following
treatment without (−) or with (+) Wnt5a of CLL cells transfected with Ctrl-siRNA or siRNA specific for 14-3-3ζ. Whole-cell lysates also were
examined via immunoblot analysis for total RhoA or Rac1. The number beneath each lane is the ratio of band densities for activated versus
total GTPase normalized for untreated samples.
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Figure 3. 14-3-3ζ enhances ROR1+ leukemia progression in vitro. (a) The mean numbers of MEC1, MEC1-Δ14-3-3ζ, MEC1-ROR1 or MEC1-ROR1-
Δ14-3-3ζ cells in triplicate wells at the days indicated below the graph. (b) The bars indicate the mean proportions of MEC1, MEC1-Δ14-3-3ζ,
MEC1-ROR1 or MEC1-ROR1-Δ14-3-3ζ cells migrating with (+) or without (− ) CCL21, as indicated at the bottom (n= 3). (c) Interaction of
ROR1 with ARHGEF2 was confirmed by immunoblot analysis of anti-ROR1 immune precipitates (ip) using lysates from MEC1-ROR1 or MEC1-
ROR1-Δ14-3-3ζ cells. (d) Activated Rac1 or RhoA were measured in MEC1, MEC1-Δ14-3-3ζ, MEC1-ROR1 or MEC1-ROR1-Δ14-3-3ζ cells. Whole-
cell lysates also were examined via immunoblot for total Rac1 or RhoA. The numbers beneath each lane are the ratios of band densities for
activated versus total GTPase normalized for sample of MEC1 cells. Data are shown as mean± s.e.m.; *Po0.05, **Po0.01, ***Po0.001 and
****Po0.0001, as calculated using one-way analysis of variance with Tukey’s multiple comparisons test.
Figure 4. 14-3-3ζ enhances ROR1+ leukemia progression in vivo. (a) Leukemia cells were collected from the spleens of engrafted mice.
The fluorescence of cells stained with 4A5-Alexa-647 (ordinate) and anti-CD19-PE (abscissa) are shown in the contour plots. The percentages
at the top right of each contour plot indicate the proportions of cells with fluorescence above the threshold indicated by the dotted circle.
(b) The bars indicate the average numbers of CD19+ROR1+ human leukemia cells harvested from spleens of mice engrafted 2 weeks earlier
with MEC1, MEC1-Δ14-3-3ζ, MEC1-ROR1 or MEC1-ROR1-Δ14-3-3ζ cells, as indicated at the bottom of each histogram (n= 6). Data are shown as
mean± s.e.m.; ***Po0.001 and ****Po0.0001, as calculated using one-way analysis of variance with Tukey’s multiple comparisons test.
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calculate the total number of CD19+ leukemia cells per spleen for
each mouse (Figure 4b). This revealed that Rag2− /−γc
− /− mice
engrafted with MEC1-ROR1 had significantly greater numbers of
leukemia cells than did littermates engrafted with MEC1, MEC1-
Δ14-3-3ζ or MEC1-ROR1-Δ14-3-3ζ cells (Figure 4b).
The gene expression profiling of CLL samples revealed variable
expression levels of YWHAZmRNA; the median level of YWHAZmRNA
in CLL cells that expressed unmutated immunoglobulin heavy-chain
variable region genes (IGHV) (UM-CLL) was significantly higher
than that observed in CLL cells that used mutated IGHV (M-CLL)
(Supplementary Figure S4A). To validate these findings, we selected
eight UM-CLL cell samples and eight M-CLL cell samples, and
examined for expression of YWHAZ cDNA by quantitative reverse
transcriptase-PCR (Supplementary Figure S4B) and for 14-3-3ζ protein
by immunoblot analysis (Supplementary Figure S4C). Again, we found
YWHAZ expressed in all samples tested; however, we found
significantly higher levels of YMHAZ in UM-CLL than in M-CLL
(Supplementary Figure S4B). We also found significantly higher levels
of 14-3-3ζ in UM-CLL than in M-CLL by immunoblot analysis
(Supplementary Figures S4C and D). The relative levels of YWHAZ
cDNA detected by quantitative reverse transcriptase-PCR correlated
with the relative levels of 14-3-3ζ detected by immunoblot analysis
(R2=0.9254, Supplementary Figure S4E).
Serine-857 of ROR1 is required for 14-3-3ζ binding
Using methods to predict 14-3-3ζ-binding peptides, for example,
14-3-3-Pred,12 we predicted that the serine-857 (RSPS857SA) of
ROR1 was a potential 14-3-3ζ binding site, as 14-3-3ζ preferentially
binds to target proteins with two consensus RSXpSXP and
RX1-2pSX2-3S motifs.
13,14 Moreover, we found that the predicted
14-3-3ζ binding motifs in the cytoplasmic domain of ROR1 were
similar to those of other known 14-3-3ζ substrates (Figure 5a);
such motifs are evolutionarily conserved in mammals (Figure 5b).
Although studies by other investigators found phosphorylation of
the serines in the intracellular domain of ROR1 in CLL,15 we could
not verify that serine at position 857 undergoes changes in
phosphorylation from our mass spectrometry data. In addition,
as there is no antibody specific for the phospho-Serine-857 of
ROR1, we could not verify that serine 857 was phosphorylated via
immunoblot analysis. For this reason, we generated a mutant form
of ROR1 that had a serine-to-alanine substitution at position 857.
Immunoprecipitation studies revealed that 14-3-3ζ interacts with
ROR1 in MEC1-ROR1 cells, expressing wild-type ROR1, but
not in MEC1-ROR1S857A cells (Figure 5c). Fluorescence confocal
microscopy demonstrated that ROR1 and 14-3-3ζ co-localized in
MEC1-ROR1 cells; however, we did not observe co-localization of
ROR1 with 14-3-3ζ in MEC1-ROR1S857A cells (Figures 5d and e).
Accordingly, MEC1-ROR1 cells had higher levels of activated Rac1
and RhoA than MEC1 or MEC1-ROR1S857A cells (Figure 5f). These
data imply that Serine-857 of ROR1 is required for the interaction
of 14-3-3ζ with ROR1, leading to activation of ARHGEF2.
DISCUSSION
In the present study, we provide evidence that 14-3-3ζ was
necessary for the recruitment of ARHGEF2 to ROR1 and the
activation of the exchange activity of ARHGEF2 for RhoA and Rac1
in response to Wnt5a. First, we validated the Wnt5a-induced
interaction of ROR1 with 14-3-3ζ in primary CLL cells using co-
immunoprecipitation studies and immunoblot analyses. Next, we
Figure 5. 14-3-3ζ binding motif on ROR1. (a) The consensus of 14-3-3ζ binding motif. Sequence of ROR1 and other known 14-3-3ζ motifs are
shown for comparison. (b) Sequence alignment of ROR1 containing 14-3-3ζ binding motifs from different species is shown. (c) Schematic
representation of the structure of ROR1 and mutated form of ROR1 (ROR1-S857A) was shown. Interaction of ROR1 with 14-3-3ζ was confirmed
by immunoblot analysis of anti-ROR1 immune precipitates (ip) using lysates from MEC1-ROR1 (WT) or MEC1 cells transfected with ROR1-
S857A (S857A). (d) Co-localization (yellow, with arrow) of ROR1 (green) with 14-3-3ζ (red) in MEC1-ROR1 and MEC1-ROR1-S857A cells, as
indicated on the right margin of each row (objective: ×100; scale bar: 2 μm). (e) Percentage of cell area in which we detected co-localization of
ROR1 and 14-3-3ζ in MEC1-ROR1 or MEC1-ROR1-S857A cells (n= 3). Data are shown as mean± s.e.m.; *Po0.05, as determined by two-tailed
Student’s t test. (f) Activated Rac1 or RhoA were measured in MEC1 (WT), MEC1-ROR1 (ROR1) or ROR1-S857A cells (S857A). Whole-cell lysates
also were examined via immunoblot for total Rac1 or RhoA. The numbers beneath each lane are the ratios of band densities for activated
versus total GTPase normalized with respect to that of MEC1 cells.
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demonstrated that expression of 14-3-3ζ was necessary for Wnt5a-
enhanced chemokine-directed migration and proliferation of
primary CLL cells in vitro and MEC1-ROR1 cell engraftment ability
in vivo. Furthermore, the effect of 14-3-3ζ was dependent on
expression of ROR1. Thus, the present study identifies a novel
function of 14-3-3ζ as an adaptor protein that can participate in
the differential regulation of Rac1 or RhoA-induced changes in cell
behavior by localizing a GEF to ROR1 to facilitate Rac1 or RhoA-
induced signaling.
14-3-3ζ belongs to a family of scaffold proteins that are involved
in many important cellular functions and that regulate multiple
signal transduction pathways.16,17 14-3-3 proteins are adaptor
proteins that bind to a variety of cellular targets, including the pro-
apoptotic protein Bad, Raf kinase, cell cycle-dependent phospha-
tase Cdc25 and others.18 Thus, 14-3-3 binding may regulate the
activity of these proteins and their ability to interact with other
components of intracellular signaling pathways.
14-3-3 proteins have been defined as phosphoserine-binding
proteins, which bind to the consensus motif RSXpSXP.13 Two
different binding motifs have been identified: RSXpSXP (mode I)
and RXY/FXpSXP (mode II).7,13,19 In addition to these two canonical
binding motifs, 14-3-3 can bind to the extreme COOH terminus of
several proteins, recently defined as a mode III binding site.20,21
Studies have identified another 14-3-3-binding motif in Cbl,
namely RX1-2SX2-3S,
14 which has been found in Keratin 1822 and
PKCμ.23 After analyzing the sequence of ROR1 for potential 14-3-3
binding sites, we identified a motif, RSPSSAS, which was located in
the serine/threonine-rich domain at positions 854-860 of ROR1
that was consistent with both mode I and Cbl-like motifs.
Although we could not verify that serine-857 in this motif was
phosphorylated in CLL cells or that 14-3-3ζ directly bound to this
ROR1 motif in vivo, our studies demonstrate that substitution of
alanine for serine at position 857 effectively abrogated the
capacity of ROR1 to complex with 14-3-3ζ.
The present findings also extended our understanding of the
importance of 14-3-3ζ in ROR1-dependent Wnt5a-induced signal-
ing. We found that reducing expression of 14-3-3ζ via RNA
interference impaired the capacity of Wnt5a to: (1) induce
recruitment of ARHGEF2 to ROR1, (2) enhance the in vitro
exchange activity of ARHGEF2 for RhoA and Rac1, and (3) induce
the activation of RhoA and Rac1 in primary CLL cells. In addition,
MEC1-ROR1 had significantly higher rates of proliferation or
migration than MEC1-ROR1-Δ14-3-3ζ cells, which in turn had rates
of proliferation or migration comparable to those of MEC1 cells or
MEC1-Δ14-3-3ζ lacking expression of ROR1. Moreover, we found
that 14-3-3ζ was required for the engraftment/growth advantage
of MEC1-ROR1 over MEC1 cells in vivo. Although we found 14-3-3ζ
expressed in each CLL sample examined, we found higher levels in
CLL cells that use UM-IGHV than in CLL cells that express M-IVHG,
prompting us to speculate that the relative level of 14-3-3ζ
contributes to the noted aggressive clinical behavior of UM-CLL
relative to that of M-CLL.24 In any case, we conclude that 14-3-3ζ is
the isoform of 14-3-3 that has a key role in ROR1-dependent
Wnt5a signaling in CLL.
Prior studies noted that 14-3-3ζ also could mediate integrin-
induced activation of cdc42 and Rac1.25 Moreover, 14-3-3ζ may
interact with ARHGEF2 and help regulate ARHGEF2 activity, which
can induce Rho- and Rac-mediated signaling.26 Similar to our
findings, 14-3-3ζ was reported to mediate the recruitment of the
Rac1-GEF, Tiam1, to β1-integrin complexes, which also resulted in
activation of Rac1.27 Unlike Tiam1, which only is expressed by
activated lymphocytes and activated CLL cells, and appears
unable to enhance mobility of CLL cells,28 ARHGEF2 is expressed
by resting lymphocytes and can promote CLL proliferation and
migration.6,29
In summary, the present study describes a previously unrecog-
nized ROR1/14-3-3ζ/ARHGEF2-dependent mechanism for generat-
ing active Rac1 or RhoA in Wnt5a/ROR1 signal that contributes
to CLL proliferative or motile behaviors. The findings reported
here demonstrate the importance of 14-3-3ζ in ROR1-dependent
Wnt5a-induced signaling and highlight a pathway for potential
drug development. To this end, we found that the capacity of
Wnt5a to induce ROR1 to associate with 14-3-3ζ could be blocked
by cirmtuzumab, a first-in-class humanized mAb specific for a
functional epitope in the ROR1-extracellular domain that is being
evaluated in patients with CLL (https://clinicaltrials.gov/ct2/show/
NCT02222688).30 Moreover, we found that cirmtuzumab could
block the capacity of Wnt5a to induce recruitment of 14-3-3ζ to
ROR1 and activation of ARHGEF2 contributing to the noted
capacity of cirmtuzumab to block ROR1-dependent non-canonical
Wnt5a signaling responsible for enhanced leukemia-cell prolifera-
tion. As such, these studies support the rationale for clinical
evaluation of this antibody in patients with CLL.
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